Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
This is a phase II open-label, one-arm, multicenter study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) treatment for patients with advanced biliary tract carcinoma.
Advanced Biliary Tract Carcinoma
DRUG: Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur
R0 resection rate, The proportion of patients with negative resection margin among patients undergoing surgery, up to 2 years|1-year event-free survival (EFS) rate, The proportion of patients with first documented recurrence or disease progression as determined by the investigator, or death from any cause, whichever occurs first., up to 1 year
Enrolled participants should be treated with neoadjuvant camrelizumab and apatinib and GEMOX, after surgery, be treated with adjuvant camrelizumab and tegafur.